AP2-associated kinase 1 (AAK1)

Class

Once-daily, oral, selective small-molecule AAK1 inhibitor (Lexicon Pharmaceuticals; also known as LX9211). AAK1 was identified as a pain target through Lexicon's Genome5000 gene-function screening program. Note: this is a different compound and different mechanism from Vertex's VX-993/suzetrigine NaV1.8 program, despite both being investigated in the same DPNP indication — no merge warranted.

Pathway

AAK1 inhibition is proposed to modulate reuptake/recycling of neurotransmitters involved in pain signaling, producing analgesia without engaging opioid receptors.

AAK1 is a serine/threonine kinase that regulates clathrin-mediated endocytosis, the process by which cells internalize surface receptors and later recycle them back to the membrane. By phosphorylating a subunit of the adaptor protein complex AP2, AAK1 controls how efficiently neurotransmitter receptors and transporters are removed from the neuronal surface and returned to it, shaping how strongly a synapse responds to ongoing neurotransmitter release. In chronic pain states, sensitized peripheral and spinal neurons show altered receptor trafficking that sustains exaggerated pain signaling. Inhibiting AAK1 is proposed to normalize this trafficking, dampening transmission along nociceptive (pain-sensing) pathways without directly engaging opioid receptors, the target of conventional narcotic analgesics. This distinguishes AAK1 inhibition mechanistically from opioid-based pain therapy and underlies interest in the target for neuropathic pain conditions, where nerve damage produces persistent, often treatment-resistant discomfort. Because AAK1 acts upstream of multiple receptor systems rather than blocking a single one, its inhibition offers a route to reduce pain signaling broadly rather than through one neurotransmitter axis, though this same breadth means downstream consequences are less thoroughly mapped than for long-established analgesic targets. The appeal lies in an oral, non-opioid option for a disease area with substantial unmet need given limited efficacy and tolerability of existing agents.